High Dose Candesartan Versus Quinapril for Restenosis Prophylaxis After Stent Angioplasty

T

Technische Universität Dresden

Status

Completed

Conditions

Arterial Occlusive Diseases

Treatments

Drug: candesartan (drug) or quinapril (drug)

Study type

Interventional

Funder types

Other

Identifiers

NCT00154050
IKPD KARDCHEM 02-04

Details and patient eligibility

About

The study is designed to test the hypothesis that high dose candesartan treatment compared to quinapril is able to reduce intima hyperproliferation and the restenosis rate after stent angioplasty in peripheral occlusive artery disease.

Full description

Patients are randomly assigned to treatment with either candesartan 32 mg/d or Quinapril 20 mg/d before the angioplasty. Walking distance, intima media thickness and crurobrachial pressure ratios are compared after 6 weeks, 3 months and 6 months. After 6 months an angiographic control is performed.

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • male and female
  • peripheral occlusive arterial disease Stad IIb Fontaine classification

Exclusion criteria

  • patients with lesions not available for PTA
  • renal insufficiency
  • patients on calcium-antagonists

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems